CommercialReimbursementMedium impact
Summary of Provider Newsroom U.S. commercial medical articles
Cigna·Allergy & Immunology, Pharmacy, Oncology·General
Effective date
Aug 1, 2026
We identified it
Aug 4, 2026
Summary
This is a newsroom summary document aggregating July 2026 policy updates from Cigna Healthcare, including several items requiring billing team attention: discontinuation of Individual & Family Plans (IFPs) effective January 1, 2027, updates to the National Injectable and Immunization Fee Schedule (NIIFS) effective August 1, 2026, changes to specialty medical injectables with reimbursement restrictions, and acceptance of Kyxata as an alternative to Carboplatin for existing prior authorizations. The document is informational and links to detailed policy articles rather than providing specific billing code changes.
Action Required
By August 1, 2026: Billing team must obtain and implement the updated NIIFS (National Injectable and Immunization Fee Schedule) third quarter 2026 update for all immunization and injectable drug reimbursement claims. Review the updated Specialty Medical Injectables with Reimbursement Restriction list and update billing system to reflect new restrictions. By December 31, 2026: Verify all active patients with Cigna Healthcare Individual & Family Plans (IFPs) are aware coverage ends December 31, 2026, and confirm enrollment in replacement plans. Immediately: Update prior authorization protocols to accept Kyxata as an approved alternative for patients with existing Carboplatin prior authorizations during the manufacturing shortage. Access the full policy articles linked in the newsroom summary to obtain specific HCPCS codes affected by NIIFS and specialty injectable restrictions, as this summary document does not provide granular billing code details.